POR and Training Program on Multidrug-Resistant Organisms

摘要 抗菌素耐药性(AMR)是最紧迫的公共卫生优先事项之一。AMR被认为是重新- 美国有超过3.5万人死亡，预计到2050年全球将有3亿人死亡。我的 最初的K24应用程序旨在提高我进行以患者为中心的抗生素研究(POR)的能力 抵制和指导新一代临床医生科学家在这一重要公众的不同方面 对健康的威胁。在K24奖的支持下，我能够显著增加我的研究组合Launch 一个微生物基因组学任务，并增加我的指导活动。因此，这个委员会的首要目标是-- 请愿性的K24更新是通过继续和进一步加强来完全过渡到既定的调查员 我的POR组合和指导能力。我的目标也是加强我的领导能力，以扩大雄心勃勃的 搜索和培训计划，重点是AMR。在我最初的K24奖的部分支持下，我创立了Cen- UTHealth的抗菌素耐药性和微生物基因组学(CARMiG)。CARMiG的愿景是 融合休斯顿德克萨斯医疗中心(TMC)提供的世界级专业知识，作为 主要为前沿研究计划提供平台，并将培训任务整合到最高水平。我也是 领导创建墨西哥湾沿岸抗菌素耐药性联盟(GCC-抗菌素联盟)，这是一个跨机构 跨TMC的AMR研究人员互动和促进协作的中心。我们制定了一套强有力的培训 AMR计划，招聘和支持不同受训人员的职业生涯(医学博士、博士和药学博士) 在他们职业生涯的不同阶段。我的实习生获得了4个NIH K开发奖(2个完美 分数)，以及同等的独立补助金。此外，实习生出版物的数量显著增加 扩大(94本出版物为第一本/通讯作者)。我们的NIH拨款组合也增加了20多美元 在过去的5年中，NIH以PI的身份获得了100万美元的赠款，包括最近的P01计划(1100万美元)。我们也是 能够获得第一个关于AMR的博士后跨机构T32培训项目。因此， 我最初的K24课程使我处于一个理想的位置，可以维持并进一步加强我的研究和培训 目标。在我最初的K24计划中，我专注于万古霉素耐药的临床和基因组方面 肠球菌(VRE)是临床上最具挑战性的细菌之一。使用在中获得的专业知识 VRE，我的K24续订将支持新的研究领域，包括微生物组科学和 革兰氏阴性杆菌的AMR、基因组学和分子流行病学以及机器学习在ES-Es中的应用 感染多药耐药菌(MDRO)的患者存在临床/基因组相关性。斯派西-- CICIC的目标是：i)加强我与AMR相关的POR组合，作为学员发展其 职业生涯，以及ii)在翻译和POR方面指导有才华的年轻调查人员，重点是AMR。我打算骗你- 调整我的强大的指导计划，该计划整合了对 耐药性及其在临床实践中的转化。

ABSTRACT Antimicrobial resistance (AMR) is one of the most pressing public health priorities. AMR is thought to be re- sponsible for more than 35,000 deaths in the US with a projection of 300 million deaths worldwide by 2050. My original K24 application sought to increase my ability to conduct patient oriented research (POR) on antibiotic resistance and mentor a new generation of clinicians scientists on different aspects of this important public health threat. With support from the K24 award, I was able to markedly increase my research portfolio, launch a microbial genomics mission and increase my mentoring activities. Thus, the overarching goal of this com- petitive K24 renewal is to fully transition to an established investigator by continuing and further strengthening my POR portfolio and mentoring abilities. I also aim to fortify my leadership skills to expand an ambitious re- search and training program, focused on AMR. Supported in part by my original K24 award, I founded the Cen- ter for Antimicrobial Resistance and Microbial Genomics (CARMiG) at UTHealth. The vision of CARMiG was to amalgamate the world-class expertise available in the Houston’s Texas Medical Center (TMC) to serve as a major platform for cutting edge research programs and integrate a training mission to the highest level. I also led the creation of the Gulf Coast Consortium on Antimicrobial Resistance (GCC-AMR), an inter-institutional hub for AMR researchers across the TMC to interact and foster collaborations. We developed a robust training program on AMR, recruiting and supporting the career of a diverse pool of trainees (MD, PhDs and PharmDs) at different stages of their careers. My trainees have secured 4 NIH K developments awards (2 with perfect scores), and equivalent independent grants. Furthermore, the number of trainee’s publications has markedly expanded (94 publications as firs/corresponding author). Our NIH grant portfolio also grew with more than $ 20 million brought in as PI of NIH grants in the last 5 years, including a recent P01 program ($11m). We were also able to secure the first post-doctoral inter-institutional T32 training program on AMR. Thus, the foundations of my initial K24 program put me in an ideal position to sustain and further strengthen my research and training objectives. In my original K24 program I focused on the clinical and genomic aspects of vancomycin-resistant enterococci (VRE) one of the most challenging organisms in clinical settings. Using the expertise acquired in VRE, my K24 renewal will support new areas of research, including the intersection of microbiome science and AMR, genomics and molecular epidemiology of Gram-negative pathogens and use of machine learning to es- tablish clinical/genomic correlates in patients infected with multidrug-resistant organisms (MDRO). The spe- cific aims are: i) strengthen my portfolio of POR related to AMR as the foundation for trainees to develop their careers, and ii) mentor talented young investigators in translational and POR focused on AMR. I plan to con- tinue my robust mentoring program that integrates the understanding of the molecular and genomic bases of resistance and their translation into clinical practice.